Abstract 4887
Background
Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor, comprising less than 1% of head and neck neoplasms. Adjuvant radiotherapy (aRT) is suggested for late-stage disease (stage III or IV); however, recent evidence suggests that it may be associated with improved survival even for early-stage disease. Moreover, the prognostic significance of tumor location on overall (OS) and ACC-specific (ACC-S) survival is unclear. We sought to address these knowledge gaps via analyses of the Surveillance, Epidemiology and End Results (SEER) database.
Methods
Intraoral minor (m) and major (M) ACCs from the SEER database (1973-2015) were selected for analysis. Information on age, sex, race, site, stage, treatment and survival was retrieved. The associations of tumor site and aRT with OS and ACC-S were estimated using hazard ratios (HR) and corresponding 95% confidence intervals (CI) obtained via Cox regression models adjusted for covariates as appropriate. Analyses were done using Stata 15.1 (StataCorp LP, College Station, TX).
Results
There were 635 minor and 1,064 major (parotid: n = 547, submandibular: n = 470, sublingual: n = 47) ACC cases included in the analyses. Late-stage patients (49% of total) were significantly more likely to have received aRT (76% vs. 66%; P < 0.01) compared to those with early-stage disease. Submandibular was the only tumour site that demonstrated statistically significant survival differences compared to the other sites; i.e., worse OS (HR = 1.4; 95% CI = 1.1-1.8) and ACC-S (HR = 1.7; 95% CI = 1.2-2.3) compared to minor ACCs. This difference was only evident for late-stage tumours: stage IV submandibular cases had worse OS (HR = 2.1; 95% CI = 1.5-2.8) and ACC-S (HR = 2.4; 95% CI = 1.7-3.4) compared to stage IV minor ACCs. Overall, aRT was associated with better OS (HR = 0.7; 95% CI = 0.6-0.9) and ACC-S (HR = 0.8; 95% CI = 0.6-1.1). This beneficial effect was more pronounced and statistically confirmed only in stage IV disease.
Conclusions
These results, based on SEER data, suggest that aRT is associated with favorable survival only in late-stage ACC and that, among these late-stage tumors, submandibular gland ACCs have substantially worse prognosis than other sites, irrespective of aRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Academy of Athens PhD Scholarship to Jason Tasoulas; UNC Lineberger Tier 3 Developmental Award funds and the University Cancer Research Fund to A.L. Amelio.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract